The FTA-ABS test (Hunter, Deacon, and Meyer, 1964) has a high sensitivity due to the low dilution (1: 5) of the test serum. The specificity of this test is also of a high order, since the principle on which it is based ensures removal of the group treponemal protein antibodies.
The FTA-ABS test (Hunter, Deacon, and Meyer, 1964) has a high sensitivity due to the low dilution (1: 5) of the test serum. The specificity of this test is also of a high order, since the principle on which it is based ensures removal of the group treponemal protein antibodies.
In order to have a test just as sensitive and specific as the FTA-ABS test, a technique has been developed based on a different principle and mechanism, namely a single-stage method for blocking the reaction of the Treponema pallidum (Tp) nonspecific antibodies.
The method is similar in principle to the fluorescent antibody test used by Lind (1967 Lind ( , 1968 A first washing with phosphate buffered saline pH 7-2 was followed by 30 min. contact at room temperature with rabbit anti-human globulin conjugate*. After further washing with PBS 7-2, the preparation was dried, mounted between slide and cover slip, and examined under a fluorescence microscope (Thivolet, Salussola, Sepetjian, and Monier, 1969) .
The anti-Reiter treponeme sera were prepared from rabbits which had given a negative FTA-ABS test before beginning immunization. The following procedure was used for all immunizations.
The inoculum was prepared from a culture of Reiter treponemes grown for 8 days in spirolate broth (BBL) to which 10 per cent. of sterile horse serum had been added. This antigen was introduced into rabbits first by intravenous then by subcutaneous injection. A first series of three intravenous injections were given at 5-day intervals, using 1 ml., 1 ml., and 2 ml. volumes of the Reiter treponeme suspension.
The second series of injections was administered subcutaneously at 7-day intervals, using 1 ml., 1 ml., and 2 ml. volumes of suspension, respectively. For the first two subcutaneous injections the inoculum was mixed with 1 ml. of Freund's complete adjuvant.
The Tables I and II. In the great majority of cases (171 sera out of 174) the results of the FTA blocking and FTA-ABS tests agree (Table I) . Disagreement, however, was observed in three cases (Table II) .
To prove that normal rabbit serum giving a negative response to the FTA 200 test was incapable of producing a blocking effect similar to that caused by our anti-Reiter serum, we used the sera from fifteen healthy rabbits as the diluent when five human sera giving a false positive FTA 200 test were subjected to the FTA blocking test. In no case was the original positive finding reversed.
Discussion
The choice of the one-step blocking test was realized after a comparative study of a two-step technique similar to that described by Kirdly and Kovats (1967) . The latter did not regularly produce the blocking effect wanted. Table I shows the one-step blocking test to have a high degree of sensitivity and specificity.
In ten cases in which the lack of sensitivity of the FTA 200 test led to a negative result, both the FTA-ABS and the FTA blocking test were positive. Whenever the FTA test was positive and an actual case of syphilis was involved, regardless of whether the titre was low (less than or equal to 800: 40 sera) or high (over 800: 57 sera), the blocking test was consistently positive.
The specificity of the blocking test would seem to be high, since in the five cases in which the FTA 200 test gave a biological false positive reaction and in the 45 cases in which the FTA 5 test gave a false positive result, the blocling test was negative as also was the FTA-ABS test. In addition, all fourteen subjects without syphilis were negative in the blocking test.
We found, however, that in three cases the results of the FTA-ABS and FTA blocking tests differed (Table II) .
In these cases the inhibiting power of the antiReiter serum used was apparently inadequate, since the FTA-ABS test and TPI test were negative and the FTA blocking test positive. This raises the problem of anti-Reiter sera varying in activity and efficacy from one production batch to another.
The human sera involved, Nos. 1, 2, and 3 (Table   II) 
